西班牙α-1抗胰蛋白酶缺乏症诊治临床实践指南:2026更新
该指南由西班牙肺病与胸外科协会(SEPAR)采用GRADE与ADOLOPMENT框架制定,系统更新了α-1抗胰蛋白酶缺乏症(AATD)的诊断与治疗推荐。指南推荐对所有COPD患者在诊断时、成人起病哮喘伴持续气流受限者及不明原因支气管扩张者进行AATD检测,并推荐对特定严重基因型且AAT<57.2mg/dL、CT证实肺气肿且肺功能受损的非活动性吸烟者给予增强治疗。
要点
- 所有COPD患者在诊断时均应检测AATD。
- 成人起病哮喘伴持续气流受限及不明原因支气管扩张者也应检测。
- 血清AAT<116mg/dL且CRP正常者行基因型或表型两步诊断。
核心结论
- AATD仍存在严重诊断不足和延迟诊断,许多重度缺乏者未能获得疾病特异性咨询或个体化照护。
- 新指南基于系统评价与专家意见更新了AATD的检测和增强治疗推荐。
研究设计与样本
- 西班牙肺病与胸外科协会(SEPAR)制定的临床实践指南。
- 采用GRADE和ADOLOPMENT框架进行系统评价,并结合更新文献综述与专家意见形成推荐。
主要发现
- AATD是一种遗传性疾病,以血α-1抗胰蛋白酶(AAT)水平降低为特征,主要增加肺气肿和肝脏受累风险。
- 自2015年SEPAR发布COPD相关AATD检测与治疗文件以来,已出现新的诊断方法和增强治疗研究。
关键数值与推荐
- 推荐对所有COPD患者在诊断时检测AATD。
- 推荐对成人起病哮喘伴持续气流受限者检测AATD。
- 推荐对不明原因支气管扩张者检测AATD。
- 对免疫比浊法测得血清AAT<116mg/dL且CRP正常者,推荐血清AAT水平联合基因型或表型的两步诊断法。
- 对记录有严重AATD、严重缺乏相关基因型且AAT<57.2mg/dL(<11μmol/L)、CT证实肺气肿且肺功能检查受损、已接受最佳药物和非药物治疗且非活动性吸烟者,推荐增强治疗。
临床怎么用
- 在COPD诊断时常规筛查AATD,并覆盖成人起病哮喘伴持续气流受限及不明原因支气管扩张人群。
- 对AAT<116mg/dL且CRP正常者,进一步行基因型或表型检测以明确诊断。
- 对符合严重AATD、AAT<57.2mg/dL、CT肺气肿、肺功能受损且非活动性吸烟等条件者,考虑增强治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Arch Bronconeumol. 2026 Jun 13:S0300-2896(26)00219-X. doi: 10.1016/j.arbres.2026.06.004. Online ahead of print. ABSTRACT Alpha-1 antitrypsin deficiency (AATD) is a genetic condition characterized by reduced blood levels of alpha-1 antitrypsin (AAT), which confers an increased risk of developing several disorders throughout life, mainly pulmonary emphysema and liver involvement. AATD remains substantially underdiagnosed and is often diagnosed late; consequently, many individuals with severe deficiency do not benefit from disease-specific counseling or tailored care modifications. Since 2015, when the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) published an updated document on the detection and treatment of patients with chronic obstructive pulmonary disease (COPD) associated with AATD, new diagnostic procedures and studies on augmentation therapy have been developed. A systematic review was conducted using the GRADE and ADOLOPMENT frameworks, with an updated literature review that, together with expert opinion, served as the basis for formulating recommendations. Testing for AATD is recommended in all individuals with COPD at the time of diagnosis, in individuals with adult-onset asthma and persistent airflow obstruction, and in individuals with bronchiectasis of unknown etiology. We recommend a 2-step diagnostic approach combining serum AAT levels and characterization of the genetic defect (genotype) or protein abnormality (phenotype) in individuals with AAT concentrations below 116mg/dL, as measured by immunonephelometry, and with a normal C-reactive protein (CRP) level. The panel recommends augmentation therapy for patients with documented severe AATD, with a genotype associated with severe deficiency and AAT levels <57.2mg/dL (<11μmol/L), and with emphysema documented on computed tomography and impaired pulmonary function test results, who are receiving optimal pharmacologic and nonpharmacologic treatment and are not active smokers. PMID: 42392940 | DOI: 10.1016/j.arbres.2026.06.004
引用
- 指南共识 · 慢阻肺:Spanish Clinical Practice Guidelines for the Diagnosis and Management of Alpha-1 Antitrypsin Deficiency: 2026 Update
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。